Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression

E. May1, H. Mouriesse2, F. May-Levin3, J.F. Qian4, P. May1 & J.C. Delarue5

1Laboratory of Molecular Oncology IRSC, 7 rue Guy Moquet, 94802 Villejuif Cedex; 2Department of Medical Statistics, 3Department of Medicine and 4Hormonal Biochemistry Laboratory, Institut Gustave-Roussy, 9405 Villejuif Cedex, France.

Summary We recently defined a new early prognostic factor, the ER*(R) status, which permits the discrimination of a group presenting a high risk of early relapse among the ER+ patients. This group was referred to as ER*(R2) in contrast to ER*(R1) which corresponded to the group of ER+ patients having a lower risk of early relapse. Taking into account the whole population including the ER0 and inflammatory tumours, we have extended this view and showed that ER*(R) status is a significant predictor of disease-free survival. Determination of c-erbB-2 mRNA levels in the same series of tumours showed that high expression of c-erbB-2 mRNA is significantly correlated with ER+, inflammatory tumours and with lymph nodes involvement. Moreover, a multivariate analysis showed that c-erbB-2 mRNA overexpression was a significant predictor of early relapse (P<0.02), as significant as ER negativity and ER*(R2). For ER+ patients a high level of c-erbB-2 mRNA constitutes a higher risk of relapse for both ER*(R1) and ER*(R2) patients. However, in the case of ER- patients, early relapses were strongly correlated with c-erbB-2 overexpression. The counterpart of this observation is that ER0 patients with no overexpression of c-erbB-2 constitute a group with a relatively good prognosis.

Management of breast cancer treatment depends on a good knowledge of the prognostic factors enabling the identification of patients with either a low or high risk of recurrence. A knowledge of the steroid receptor status, specifically the oestrogen receptor (ER), should allow the prediction of the response to hormonal therapy and to some extent disease-free survival, site of relapse and overall survival (Knight et al., 1977; Pichon et al., 1980; Clark et al., 1983; Allegra et al., 1979; Blanco et al., 1984; Fisher et al., 1983; Hahnel et al., 1979; Saez et al., 1983). Although there is a general agreement on the higher risk of relapse for receptor-negative (ER-) patients, the prognostic value of ER status is not accepted by all authors (Aamdal et al., 1984; Howell et al., 1984; Felman et al., 1986; Parl et al., 1984). Among ER-positive (ER+) patients regarded as having a more favourable prognosis, we have recently defined a group presenting a high risk of relapse (May et al., 1989). This group of patients, called ER*(R2), has been characterised by a ratio of (ER-protein in fmol per mg total proteins) to (ER-mRNA in pg per 4 μg total RNA) higher than 1.5. According to these results, ER*(R) status has been assigned as an early prognostic factor.

On the other hand, amplification of the c-erbB-2 gene is an alteration frequently associated with breast cancer. This gene encodes a transmembrane protein that shows extensive homology with the receptor for epidermal growth factor (Coussens et al., 1985; Bargmann et al., 1986; Yamamoto et al., 1986), indicating that c-erbB-2 is a membrane-bound receptor. A ligand for c-erbB-2, however, has not yet been identified. A number of studies regarding amplification of this gene in primary human breast cancer has been published (see Table I for references). Depending on the authors, incidence of amplification varies from 10 to 40%. Amplification of c-erbB-2 receptor gene in human breast cancer was associated with high levels of both mRNA and protein (see Table I for references). However, overexpression of the c-erbB-2 gene depends not only on gene amplification, since elevated levels of the c-erbB-2 receptor and c-erbB-2 specific mRNA were observed in tumours containing a single copy of the oncogene (Lacck et al., 1989; Berger et al., 1988; Guerin et al., 1989; Venter et al., 1987).

The association between amplification of the c-erbB-2 gene and poor prognosis in human breast cancer was first reported by Slamon et al. (1987). Since then, contradictory results concerning the associations between c-erbB-2 amplification, clinicopathological features and risk of relapse have been reported (see Table I). It is interesting to note that significant associations between c-erbB-2 amplification and positive nodal status as well as the worst histological grade and increase in relapse are observed more often in the groups of patients having a higher incidence of amplification and/or overexpression. In fact, recent results of Slamon et al. (1989), Wright et al. (1989) and Tandon et al. (1989) obtained with large populations of patients strongly support the assumption that c-erbB-2 gene amplification and/or overexpression are reliable guides to the prognosis of breast cancer.

The present study was performed in an attempt to correlate the prognostic significance of ER*(R) status with the c-erbB-2 prognostic factor. As direct measurement of c-erbB-2 gene expression may be more relevant to disease (Tandon et al., 1989), we have assessed the level of c-erbB-2 specific mRNA in the series of breast cancers previously analysed for the expression of ER-specific mRNA (May et al., 1989). Results showed that ER*(R) status and c-erbB-2 mRNA are two significant independent predictors of early relapse.

Materials and methods

Patients

Samples of untreated and non-metastatic breast carcinomas were obtained by biopsy or tumorectomy from 89 patients treated at ‘Institut Gustave-Roussy’ (Villejuif, France). Seventy-six patients had an operable tumour. Depending on the tumour size, either mastectomy or conservative treatment was performed. In case of axillary nodes invasion, adjuvant treatment was prescribed: taximofen for post-menopausal women, chemotherapy for premenopausal women with loco-regional radiotherapy for both groups of patients. The remaining 13 patients had an inflammatory non-metastatic tumour. This diagnosis was made on the basis of clinical symptoms (oedema, hotness, redness in more than one-third of the breast) and confirmed by biopsy. These patients were treated by association of chemo-, radio- and hormone-therapy. No surgery was performed.

Correspondence: E. May.
Received 4 January 1990; and in revised form 22 February 1990.
Table I Results obtained by different groups concerning the association between c-erbB-2 amplification or overexpression and disease parameters

| Authors            | Amplif. or overexpr. (%) | ER status | Histological grade | Node status | IBC* | DFS* |
|--------------------|--------------------------|-----------|--------------------|-------------|------|------|
| Ali et al. (1988)  | 122                      | NS        | NS                 | NS          | NS   | NS   |
| Zhou et al. (1989)| 157                      | NS        | NS                 | NS          | NS   | NS   |
| Van de Vijver et al. (1987) | 95            | NS        | NS                 | NS          | NS   | NS   |
| Zeillinger et al. (1989) | 291         | 0.02      | NS                 | NS          | 0.046| 0.0002|
| Lacroix et al. (1989) | 57           | NS        | 0.095              | NS          | 0.046| 0.0002|
| Varley et al. (1987) | 37           | NS        | NS                 | NS          | NS   | NS   |
| Guérin et al. (1988) | 115          | <10-3     | NS                 | <0.02       | 0.001| 0.01 |
| Berger et al. (1988) | 51           | 0.01      | 0.0002             | 0.18        | 0.01 |
| Guérin et al. (1989) | 221          | 0.01      | <0.001             | 0.01        | <10-4|
| Slamon et al. (1987) | 86           | 0.05      | 0.06               | 0.01        | 0.01 |
| (1989)              | 345          | 0.05      | 0.06               | 0.01        | 0.01 |

*NS, not significant. †Inflammatory breast carcinoma. ‡Disease-free survival. ‘Overexpression was measured at either the protein or transcription level’. §Parameter analysed was the nuclear grade. ¶Patients with positive nodes. 'Correlation observed for infiltrating ductal tumours. Clinical stage II breast cancer. ¶Per cent of patients with a strong membrane staining. Correlation observed for patients with positive nodes.

Tissue samples

After histological verification, the samples selected by the pathologist were carefully dissected, frozen and stored in liquid nitrogen until required. Stromal cell contamination was estimated for each sample. The levels of contamination were scored by eye from ‘+ ’ for less than 10% to ‘ ++ ’ for a concentration of more than 50% of stroma cells. High stroma cell concentration was detected in only 11 tumours and distributed over the different groups of patients.

Chemicals

1H-oestradiol (1H-E2; 100 Ci mmol−1) was obtained from the CEA (Commissariat à l’Energie Atomique, France). All other reagents were of the highest grade available.

ER assay

ER levels were determined by the one-dose saturation method (5 nM) using 1H-E2 as previously described (Martin et al., 1981). The total amount of receptor was measured after extraction with a buffer containing 0.4 M KCl. Tumours with an ER level higher than 10 fmol mg−1 of total protein were considered as positive.

RNA extraction

Total cellular RNA was isolated from 0.3 to 0.5 g of frozen tumour by the guanidinium-caesium chloride method (Gillis et al., 1974). Yields were quantified by spectrophotometry. The quality of RNA was monitored by controlling the integrity of the 28 S and 18 S ribosomal bands following agarose gel electrophoresis.

Northern blot analysis

Total RNA (4 µg) was analysed by Northern blot as previously described (May et al., 1989). Hybridisation of filters was performed after treating Hybond N membrane (Amersham) for 1 h in Tris-HCl 0.005 M, EDTA 0.002 M, Denhart (pH 8) at 65°C. RNA concentrations were determined by quantitative densitometric scanning of appropriately exposed autoradiograms. Quantification was performed by running in parallel known amounts of a single-stranded recombinant DNA containing the insert used as probe. Each sample was analysed at least twice and results were normalised relative to the steady state level of β-actin mRNA. Two aliquots of RNA extracted from the tumour of patient no. 60 were run on every gel and used as reference for comparison purposes.

The following DNA or plasmid probes were used in this study after 32P-labelling by the ‘random primed’ DNA labelling method (Boehringer Kit, Manheim); the 1200-bp Accl/ BamHI fragment of pMAC117 (ATCC collection) specific to the c-erbB-2 mRNA and chicken-specific β-actin (May et al., 1989).

Statistical methods

Survival times were measured from the date of diagnosis and the multiple regression model developed by Cox (1972) for censored survival data was used. This both allows the consideration of several variables simultaneously and the identification of the variables which have an important effect on disease recurrence and survival. Disease-free survival (DFS) curves were obtained by the product limit method of Kaplan and Meier (1958). Comparisons of DFS curves were based on the log rank test and all other comparisons were made using the χ2 test.

Results

c-erbB-2 mRNA expression and correlation with other prognostic factors

We have previously quantified the ER-binding activities and the steady-state levels of ER-mRNA for untreated, primary breast carcinomas (May et al., 1989). In the current study, we performed a quantitative analysis of steady-state levels of c-erbB-2 mRNA on the same RNA preparations except for one additional ER+ carcinoma.

Figure 1 shows a representative Northern mRNA blot obtained from 13 different tumours. A 4.8 kb mRNA species was detected in positive samples. Quantification of c-erbB-2 mRNA was performed as described in Materials and methods.

EARLY RELAPSE, ER AND c-erbB-2 LEVELS 431
and expressed in pg per 4 μg of total RNA. c-erbB-2 mRNA amounts displayed a wide range of values from less than 5 pg to as much as 190 pg. Under our experimental conditions, the level of c-erbB-2 transcripts in the MCF-7 cell line corresponded to less than 5 pg per 4 μg of total RNA. This is likely to reflect the normal level of expression. The MCF-7 cells show similar expression to that of normal mammary epithelial cells and fibroblasts (Kraus et al., 1987). Fifty-seven per cent of the population correspond in fact to this c-erbB-2 mRNA level (Figure 2). The remaining patients were divided into four equal groups corresponding to 5–10, 10–20, 20–50 and 50–190 pg of specific mRNA per 4 μg of total RNA, respectively (Figure 2). These groups were analysed to establish the cut-off value of c-erbB-2 mRNA that would best distinguish patients at high risk of relapse. A cut-off value of 20 turned out to provide a significant separation. Our population of 89 patients was then separated into three categories corresponding to normal (less than 5 pg), moderate (5–20 pg) and high (20–190 pg) level expression. High levels of c-erbB-2 mRNA were detected in 23% (20/89) of tumours (Table II).

Correlations between clinico-pathological data and the level of c-erbB-2 mRNA expression are presented in Table II. We have included the ER* (R) status according to previously published results (May et al., 1989). This parameter, estimated for ER+ tumours, was defined by the ratio ER-protein (expressed in fmol mg⁻¹) to ER-mRNA (expressed in pg per 4 μg of total RNA). Groups ER*(R1) and ER*(R2) correspond to tumours having a ratio lower and higher than 1.5, respectively.

Results presented in Table II showed that high levels of c-erbB-2 mRNA were significantly correlated with (i) inflammatory carcinoma (P < 0.007), (ii) presence of involved lymph nodes (P = 0.03) and (iii) ER negativity (P = 0.02). There was no significant correlation between c-erbB-2 mRNA levels and age of the patient at diagnosis, histological grade or ER+(R) status.

Table II  c-erbB-2 transcription in relation to the clinico-pathological and biological characteristics of 89 patients with breast cancer

| Parameters                  | Classes | Normal | Moderate | High | Total | p values |
|-----------------------------|--------|--------|----------|------|-------|----------|
| Age at diagnosis (years)    |        |        |          |      |       |          |
| <40                         | 51     | 18     | 20       | 18 (23%) | 89    |          |
| 40–60                       | 25     | 5      | 10       | 40   | NS    |          |
| >60                         | 20     | 12     | 6        | 38   |       |          |
| Clinical tumour type        | NBC    | 45 (59%) | 18 (24%) | 13 (17%) | 76  | 0.007   |
| IBC                         | 6 (46%) | 0 (0%) | 7 (54%)  | 13   |       |          |
| Histological grade          | I      | 3      | 2        | 0    | 5     |          |
| II                          | 30     | 9      | 11       | 50   | NS    |          |
| III                         | 17     | 7      | 8        | 32   |       |          |
| Lymph nodes status          | N⁻     | 22 (63%) | 11 (31%) | 2 (6%)  | 35  | 0.03    |
| N⁺                          | 23 (56%) | 7 (17%) | 11 (27%) | 41   |       |          |
| ER status                   | ER⁻    | 10 (48%) | 2 (9%)  | 9 (43%) | 21  | 0.02    |
| ER⁺                         | 41 (60%) | 16 (23%) | 11 (16%) | 68   |       |          |
| ER+(R) status               | ER+(R)Ⅰ | 25 (62%) | 8 (20%) | 7 (18%) | 40  | NS      |
| ER+(R)Ⅱ                     | 16 (57%) | 8 (29%) | 4 (14%)  | 28   |       |          |

*Expressed in pg per 4 μg of total RNA. Depending on the level of c-erbB-2 mRNA, patients were divided into three categories corresponding respectively to normal (<5 pg), moderate (5–20 pg) and high (>20 pg) expression of c-erbB-2 mRNA. NBC, non-inflammatory breast cancer; IBC, inflammatory breast cancer. *According to the definition of Bloom and Richardson (1957), histological grading was not available for two cases. Parameter available only for non-inflammatory operable tumours (76 cases). "ER" and "ER⁺" correspond to tumours with less and more than 10 fmol ER per mg protein, respectively. "ER+(R) status was determined for ER⁺ patients by calculating the ratio ER-protein (in fmol per mg of total protein) to ER⁺ mRNA (in pg per 4 μg of total ARN). ER+(R)Ⅰ patients with a ratio < 1.5, ER+(R)Ⅱ patients with a ratio > 1.5 (May et al., 1989).
Prognostic significance of c-erbB-2 mRNA and ER-/ER+ (R) status as compared to classical prognostic factors

Univariate and multivariate analysis was performed to correlate all available prognostic factors including c-erbB-2 mRNA and ER*(R) status with disease-free survival data. Results are presented in Table III. It is important to point out that we selected for patients exhibiting a primary tumour not yet treated either by chemo-, radio- or hormono-therapy. The median follow-up available for this analysis was 30 months. Univariate as well as multivariate analysis showed that neither age at diagnosis nor histological grade were significant in predicting disease outcome. For populations reduced to operable tumours (76 patients), lymph-node involvement was also not significant. The relatively small size of our population as well as the short median follow-up available could account for this observation (Contesso et al., 1975).

In agreement with previously published data (Lacroix et al., 1989; Guerin et al., 1989), univariate survival analysis showed that patients with inflammatory carcinoma had a very poor prognosis (P<10^-9). However, this parameter loses its significance on multivariate analysis including age, histological grade, ER*/ER(+) (R) status and c-erbB-2 mRNA. This indicates that the clinical tumour type as a prognostic factor was dependent on the other significant prognostic factors.

c-erbB-2 mRNA overexpression was as significant as inflammatory tumours on univariate analysis. Moreover, high levels of c-erbB-2 mRNA (>20 pg per 4 µg of total RNA) was still highly significant on multivariate analysis in predicting relapse in the relative short-term (P<0.02). The group of patients with normal levels of c-erbB-2 mRNA (<5 pg) was taken as reference in this analysis. It is interesting to note that patients with moderate overexpression (5–20 pg) had the same low-risk of relapse as patients with normal levels of c-erbB-2 mRNA.

On the other hand, both ER* and ER*(R) status were highly significant in predicting disease outcome on univariate as well as on multivariate analysis. These analyses (Table III) were performed by grouping the 89 tumours into three groups corresponding to ER*, ER*(R1) and ER*(R2) tumours, the ER*(R1) group being reference for multivariate analysis. Both ER* and ER*(R2) patients had a high risk of early relapse (P=0.01). The risk of relapse for ER*(R2) patients is comparable to that of patients which have an overexpressed c-erbB-2 gene. Our first identification of ER*(R2) as a predictor of early relapse was performed on a population confined to ER* patients having a non-inflammatory tumour. Results presented here, extend our previous conclusion to the whole population, including ER* and inflammatory tumours.

Finally, a log rank test with DFS data was performed in order to evaluate the relative risk of relapse of patients with two poor prognostic factors, c-erbB-2 overexpressing and ER* or ER*(R2). According to our previous observation showing that patients with normal and moderate levels of c-erbB-2 mRNA had in fact the same low risk of relapse, these two groups were mixed for the present analysis. Results are presented in Table IV and Figures 3 and 4. Twenty-two relapses were observed. Most of them (18/22) were distal metastasis. The four remaining consisted of three local relapse and one contralateral cancers.

Figure 3 shows the disease-free interval for ER* patients. The ER*(R2) group was at a higher risk of relapse than the ER*(R1) group for patients having normal or moderate level of c-erbB-2 mRNA, as well as for those overexpressing c-erbB-2 mRNA. Moreover, high level of c-erbB-2 mRNA constituted an additional risk of relapse for both ER*(R1) and ER*(R2) patients.

The relationship between expression of c-erbB-2 mRNA and disease-free survival of 21 ER* patients is given in Figure 4. Eight out of nine observed relapses were associated with c-erbB-2 mRNA overexpression. This indicated that, for ER* patients, relapses were strongly correlated with c-erbB-2 gene overexpression. It is interesting to note that ER* patients expressing normal or moderate levels of c-erbB-2 mRNA constitute a group having a relative low risk of relapse, comparable to the low risk of relapse of ER*(R1) patients. In other words, ER*(R2) is a better predictor of relapse than ER negativity for patients expressing relatively low levels of c-erbB-2 mRNA (<20 pg).

### Table III: Comparison of the different factors for predicting disease-free survival

| Parameters                     | Univariate a | Multivariate analysis b |
|--------------------------------|--------------|------------------------|
| Age at diagnosis               | NS           | NS                     |
| Histological grade             | NS           | NS                     |
| Node status                    | NS           | NS                     |
| Clinical tumour type           | <10^-4       | NBC                    |
| c-erbB-2 mRNA expression       | <10^-4       | normal 1              |
| ER-/ER* status                 | 0.001        | high 4.9              |

a: Not significant. b: Significant.

### Table IV: c-erbB-2 mRNA expression versus ER*/ER*(R) status: relative risk of relapse analysed by the log rank test for 89 breast cancer patients

| c-erbB-2 | ER*/ER*(R) status | Number of cases | Expected relapses | Observed relapses | Obs/Exp |
|----------|-------------------|-----------------|-------------------|-------------------|---------|
| mRNA A   |                   |                 |                   |                   |         |
| <20      | ER*               | 12              | 2.6               | 1                 | 0.4     |
|          | ER*(R1)           | 33              | 9.5               | 2                 | 0.2     |
|          | ER*(R2)           | 24              | 5.8               | 6                 | 1       |
| >20      | ER*               | 9               | 1.1               | 8                 | 7.3     |
|          | ER*(R1)           | 7               | 2.1               | 2                 | 1       |
|          | ER*(R2)           | 4               | 0.9               | 3                 | 3.4     |

*Expressed in pg of specific mRNA per 4 µg total RNA. a As defined in the legend to Table III. P < 10^-5.

![Figure 3](image-url) Disease-free survival curves in ER-positive breast cancer patients stratified by ER*(R) groups. Top and bottom panels correspond to patients having less and more than 20 pg of c-erbB-2 mRNA per 4 µg of total RNA extracted from tumours, respectively.
Figure 4 Disease-free survival curves in ER-negative breast cancer patients stratified by c-erb-B-2 mRNA levels. c-erb-B-2 mRNA was expressed in pg per 4 μg of total RNA extracted from tumours. Two events were noted at 3 months in the group of patients overexpressing c-erb-B-2 mRNA.

Discussion

We recently defined a new early prognostic factor, the ER\(^+\)(R) status, which permits one to discriminate among the ER positive patients, a group presenting a high risk of early relapse (May et al., 1989). This group was referred to as ER\(^+\)(R2) in contrast to ER\(^+\)(R1) which corresponded to a group of ER positive patients having a lower risk of early relapse.

In the present study we performed a multivariate analysis to evaluate the prognostic significance of ER\(^+\)(R) status in relation to c-erb-B-2 mRNA overexpression and other classical parameters used in breast cancer prognosis.

Levels of c-erb-B-2 mRNA were evaluated by Northern blotting in 89 primary human breast carcinomas from non-treated patients for whom comprehensive clinical follow-up data was available. High expression of c-erb-B-2 mRNA is significantly correlated with ER negativity, inflammatory tumours and with lymph node involvement, all of which are indicators of poor prognosis. While conflicting results concerning the correlation between c-erb-B-2 gene amplification and/or overexpression and other classical prognostic factors have been reported in the literature (see Table I), our results are in agreement with those obtained by Guerin et al. (1989) from an independent population of patients from the same Cancer Institute.

Concerning the prognostic value of ER\(^+\)(R) status, we found no correlation between this factor and c-erb-B-2 mRNA. We previously showed the absence of a significant correlation between ER\(^+\)(R) status and histological grade of the tumour or lymph node involvement. Results presented here extend the assessment of ER\(^+\)(R) status as an independent prognostic factor to c-erb-B-2 gene expression.

In a multivariate survival analysis, with a median follow-up of 30 months, we found that c-erb-B-2 mRNA overexpression was a highly significant short-term predictor of relapse (P = 0.02). These results agree with those published by Varley et al. (1987), Slamon et al. (1987, 1989), Wright et al. (1989) and Tandon et al. (1989), although the medium follow-up available for our studies was shorter than that for these authors.

It is interesting to note that the level of c-erb-B-2 transcripts significant for the prediction of short-term relapse corresponds to at least 10-fold the MCF-7 level considered as normal. This observation corroborates published data showing that gene amplification correlated with the highest levels of overexpression and that the group with the highest copy number showed the greatest difference in prognosis when compared with the single copy group (Slamon et al., 1987, 1989). Therefore, analysis of c-erb-B-2 mRNA expression may be a sensitive assay provided that the cut-off value is carefully determined.

We found no correlation between lymph node involvement and early relapse. This observation is not inconsistent with previous data giving a significant value of lymph node involvement with longer available follow-up (Contesso et al., 1975). Considering this observation with the fact that c-erb-B-2 overexpression was significantly correlated with lymph node involvement and disease free survival, it is tempting to suggest that c-erb-B-2 overexpression is an earlier event than lymph node involvement towards the development or progression of breast cancer. This assumption is in agreement with the fact that an overexpression of c-erb-B-2 may be detected as early as stage I and II of mammary tumours (Lacroix et al., 1989).

On the other hand, multivariate analysis showed that the two other worst factors for predicting a poor short-term prognosis were ER negativity and ER\(^+\)(R2). Previously, we evaluated the prognostic significance of ER\(^+\)(R) status from a population restricted to ER\(^+\) patients. Here we extended this idea and showed that ER\(^+\)(R) status is a significant predictor of disease-free survival for the whole population including the ER\(^-\) patients and inflammatory tumours. In a multivariate analysis including clinical tumour type, c-erb-B-2 expression and ER\(^+\)/ER\(^-\)(R) status, inflammatory tumours are not longer significant whereas ER\(^-\) and ER\(^+\)(R2) are.

The results of the log rank test (Table IV) and the DFS curves (Figures 2 and 3) showed that patients having a particularly poor prognosis were those with tumours containing high-levels of c-erb-B-2 mRNA and either ER\(^+\) or ER\(^-\) (R2). An unexpected observation was that ER\(^-\) patients with no overexpression of c-erb-B-2 had a relatively low risk of early relapse.

In conclusion, data presented here and elsewhere (May et al., 1989) strongly suggest that both populations of ER\(^+\) and ER\(^-\) patients could be divided into two groups presenting either a low or high risk of early relapse. We found that among ER\(^+\) patients, ER\(^+\)(R2) patients had a higher risk of early relapse especially when c-erb-B-2 was overexpressed. On the contrary, we observed that ER\(^-\) patients with low or moderate amounts of c-erb-B-2 had a good short-term prognosis.

We would like to thank C. Breugnot and M. Le Maout for their excellent technical assistance. This work was supported by Clinical Research Grant 87 D7 from the Institut Gustave-Roussy and by grants from the Association pour la Recherche sur le Cancer and the Ligue Nationale Francaise contre le Cancer.

References

AAMALD, S., BORMER, O., JORGENSEN, O. & 4 others (1984). Estrogen receptors and long-term prognosis in breast cancer. Cancer, 53, 2525.

ALI, S.U., CAMPBELL, G., LIDEREAU, R. & CALLAHAN, R. (1988). Amplification of c-erb B-2 and aggressive human breast tumors. Science, 240, 1795.

ALLEGRA, J.C., LIPPMAN, M.E., SIMON, R. & 7 others (1979). Association between steroid receptor status and disease free interval in breast cancer. Cancer Treat. Rep., 63, 1271.

BARGMANN, C.I., HUNG, M.-C. & WEINBERG, A.E. (1986). The new oncogene encodes an epidermal growth factor receptor-related protein. Nature, 319, 226.

BARNES, D.M., LAMMIE, G.A., MILLIS, R.K., GULLICK, W.L., ALLEN, D.S. & ALTMAN, D.G. (1988). An immunohistochemical evaluation of c-erb-B-2 expression in human breast carcinoma. Br. J. Cancer, 58, 449.

BERGER, M.S., LOCHER, G.W., SAURER, S. & 4 others (1988). Correlation of c-erb-B-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res., 48, 1238.

BLANCO, G., ALAVAIKKO, M., OJALA, A. & 5 others (1984). Estrogen and progesterone receptors in breast cancer: relationship to tumor histopathology and survival of patients. Anticancer Res., 4, 383.
BLOOM, H.J.G. & RICHARDSON, W.W. (1957). Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed 15 years. Br. J. Cancer, 11, 359.

CLARK, G.M., MCGUIRE, W.L., HUBAY, C.A., PEARSON, O.H. & MARSHALL, J.S. (1983). Progesterone receptors as a prognostic factor in stage II breast cancer. J. Natl. Cancer Inst., 69, 1343.

CONTESSO, G., ROUSSESE, J. & GENIN, J. (1975). L'enravishment ganglionnaire locorégional des cancers du sein. Bull. Cancer, 62, 359.

COUSSENS, L., YANG-FENG, T.L., LIAO, Y.C., & 9 others (1985). Tyrosine kinase receptors with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132.

COX, D.R. (1972). Regression models and life tables. J. R. Stat. Soc. B., 34, 187.

FELDMAN, J.G., PERTSCHUK, L.P., CARTER, A.C., EISENBERG, K.G. & FLEISHER, J. (1986). Histochemical estrogen binding. An independent predictor of recurrence and survival in stage II breast cancer. Cancer, 57, 911.

FISHER, B. REDMONT, C.K. & WICKERMAN, D.L. (1983). Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy. Breast Cancer Res. Treat., 3, 355.

GLISIN, V., CRKVENJAKOV, R. & BYUS, C. (1974). Ribonucleic acid isolated by cesium chloride centrifugation. Biochemistry, 13, 2633.

GUERIN, M., BARROIS, M., TERRIER, M.J., SPIELMANN, M. & RIOU, G. (1988). Overexpression of either c-myc or c-erbB-2 neuroepithelial oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res., 3, 21.

GUERIN, M., BARROIS, M., TERRIER, M.J., SPIELMANN, M. & RIOU, G. (1988). Overexpression of either c-myc or c-erbB-2 neuroepithelial oncogenes in human breast carcinomas: correlation with poor prognosis. Int. J. Cancer, 43, 201.

HAHNEL, A., WOODINGS, T. & VIVIAN, A.B. (1979). Prognostic value of estrogen receptors in primary breast cancer. Cancer, 44, 671.

HOWELL, A., BARNES, D.M., HARKLAND, R.N. & 6 others (1984). Steroid hormone receptors and survival after 1st relapse in breast cancer. Lancet, 1, 585.

KAPLAN, E. & MEIER, P. (1958). Non parametric estimation from incomplete observation. J. Am. Stat. Assoc., 53, 457.

KNIGHT, W.A., LIVINGSTON, R.B., GREGORY, E.J. & MCGUIRE, W.L. (1977). Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res., 37, 4669.

KRAUS, M.H., POPESCU, N.C., AMSBAUGH, S.C. & KING, C.R. (1987). Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J., 6, 605.

LACROIUX, H., IGGLEHART, J.D., SKINNER, M.A. & KRAUS, M.H. (1989). Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene, 4, 145.

MARTIN, P.M., BRESSOT, N., DELARUE J.C. & 4 others (1981). Dosage des recepteurs hormonaux stéroïdien intra-tissuraire en pathologie mammaire humaine. In Evolution des moyens de diagnostic du cancer du sein, Gest, J. (ed.) p 263. J.M.T. Conseil: Paris.

MAY, E., MOURIESSIE, M., MAY-LEVIN, F., CONTESSO, G. & DELARUE, J.C. (1989). A new approach allowing an early prognosis in breast cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ER-specific mRNA level. Oncogene, 4, 1037.

PARL, F.P., SCHMIDT, B.P., DUPONT, W.D. & WAGNER, R.K. (1984). Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis and histopathologic grading. Cancer, 54, 2237.

PICHON, M.F., PALLUD, C., BRUNET, M. & MILGRÖM, E. (1980). Overexpression of estrogen receptors in human breast cancer. Breast Cancer Res. Treat., 3, 345.

SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A. & MCGUIRE, W.L. (1987). Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177.

SLAMON, D.J., GODDLEPHIN, W., JONES, I.A. & 8 others (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707.

TANDON, A.K., CLARK, G.M., CHAMNESS, G.C., ULLRICH, A. & MCGUIRE, W.L. (1989). HER-2/new Oncogene protein and prognosis in breast cancer. J. Clin. Oncol., 7, 1120.

VAN DE VUVER, M.J., PETERSE, J.L., MOOI, W.J. & 4 others (1988). Neu protein overexpression in breast cancer. N. Engl. J. Med., 319, 1239.

VAN DE VUVER, M., VAN DE BERSSELAAR, R., DEVILLE, E., CORNELIUSSE, C., PETERSE, J. & NUSE, R. (1987). Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol. Cell. Biol., 7, 2019.

VAN DE VUVER, M., VAN DE BERSSELAAR, R., DEVILLE, E., CORNELIUSSE, C., PETERSE, J. & NUSE, R. (1987). Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol. Cell. Biol., 7, 2019.

VAN DE VUVER, M., VAN DE BERSSELAAR, R., DEVILLE, E., CORNELIUSSE, C., PETERSE, J. & NUSE, R. (1987). Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol. Cell. Biol., 7, 2019.

VANDELLER, J., SWALLOW, J.E., BRAMMAR, W.J., WHITAKER, J.L. & WALKER, R.A. (1987). Alterations to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene, 1, 423.

VENTER, D.J., TUZIN, I., KUMAR, S. & GULLICK, W.J. (1987). Overexpression of the c-erbB-2 oncogene in human breast carcinoma, immunohistological assessment correlates with gene amplification. Lancet, II, 69.

WRIGHT, C., ANGUS, B., NICHOLSON, S. & 6 others (1989). Expression of the c-erbB-2 oncogene: a prognostic indicator in human breast cancer. Cancer Res., 49, 2087.

YAMAMOTO, T., IYAMA, S., AKIYAMA, T. & 4 others (1986). Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature, 319, 230.

ZIELING, R., KURY, F., CHERWENKA, K. & 11 others (1989). HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene, 4, 109.

ZOUH, D.J., AHUJ, H., CLINE, M.J. (1989). Proto-oncogene abnormalities in human breast cancer. c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene, 4, 105.